US FDA Approves Moderna’s Skin Cancer Therapy

On, February, 22, 2023, Moderna Inc. said that US regulators have given its experimental personalised mRNA skin cancer vaccine and Merck & Co.’s drug Keytruda the designation of breakthrough therapies as an additional treatment for high-risk patients. After the market closed Moderna shares rose 2.5% to $164. Based on data from a mid-stage drug study […]

Continue Reading

Moderna’s Omicron-focused Vaccine Better than Original COVID-19 Vaccine

Moderna Inc. claimed that its Omicron-focused COVID-19 vaccines had improved immune responses against BA.4 and BA.5 sub-variants of Omicron, found Moderna’s latest study. Data suggests that in adults who had been vaccinated and received booster shots, both of Moderna’s Omicron-focused vaccines, including mRNA-1273.214 and mRNA-1273.222, has produced high antibody response against BA.4 and BA.5 sub-variants […]

Continue Reading